IL-2: the first effective immunotherapy for human cancer.

Abstract

The ability of IL-2 to expand T cells with maintenance of functional activity has been translated into the first reproducible effective human cancer immunotherapies. The administration of IL-2 can lead to durable, complete, and apparently curative regressions in patients with metastatic melanoma and renal cancer. The growth of large numbers of tumor-infiltrating lymphocytes with in vitro anti-cancer activity in IL-2 has led to the development of cell transfer therapies that are highly effective in patients with melanoma. The genetic modification of T cells with genes encoding αβ TCRs or chimeric Ag receptors and the administration of these cells after expansion in IL-2 have extended effective cell transfer therapy to other cancer types.

DOI: 10.4049/jimmunol.1490019

2 Figures and Tables

02004002014201520162017
Citations per Year

824 Citations

Semantic Scholar estimates that this publication has 824 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Rosenberg2014IL2TF, title={IL-2: the first effective immunotherapy for human cancer.}, author={Steven Aaron Rosenberg}, journal={Journal of immunology}, year={2014}, volume={192 12}, pages={5451-8} }